TLR7 and melanoma: In conclusion, our study displayed that SZU-101 (a TLR7 agonist synthesized by our group) and JQ-1 (a well-defined BRD4 inhibitor) could be administrated in combination to achieve better repressive effects on tumor growth and metastasis in both murine breast cancer and melanoma models.